Jef­frey Blue­stone ex­its Park­er and switch­es fo­cus back to au­toim­mune dis­eases in cell ther­a­py 2.0 launch

Jef­frey Blue­stone is re­turn­ing to the sci­en­tif­ic field where he forged his rep­u­ta­tion as a drug hunter and top in­ves­ti­ga­tor.

The promi­nent sci­en­tist has hand­ed in his walk­ing pa­pers as CEO of the high pro­file Park­er In­sti­tute for Can­cer Im­munother­a­py, switched to the ad­junct fac­ul­ty at UCSF and is now launch­ing a new com­pa­ny, where he plans to take a hands-on role in the de­vel­op­ment of new cell ther­a­pies for au­toim­mune and de­gen­er­a­tive dis­eases.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER